Name: LSPN Europe 2026
Start: 2026-09-22 08:00
End: 2026-09-23 18:00
Location: Basel Marriott Hotel, Switzerland

Where Life Sciences IP Strategy Comes Full Circle

September 22-23rd, 2026 | Basel, Switzerland

2 Days | 150+ Attendees

Where pharma and biotech leaders shape the agenda

Balanced 1:1 Networking

Turn cutting-edge global life sciences patent prosecution and litigation insights into a stronger portfolio strategy that sets you apart in a competitive marketplace.

The 9th Annual LSPN Europe is delighted to be moving to the European Life Science Hub - Basel, Switzerland

LSPN Europe 2026 is an exclusive two-day gathering where pharma and biotech decision-makers connect, exchange candid insights, and strengthen patent portfolio strategies to meet today’s regulatory and judicial requirements.

Explore the following leading topics in 2026 alongside our 50% in-house audience:

General Counsel and Chief IP Officer - constraints, innovation, resourcing and budgeting concerns 2026

Balance growing strategic responsibilities with increasing operational constraints. Aligning IP strategy with business goals, and ensuring effective portfolio management in a rapidly changing landscape.

Exploring cost vs benefits of utilising AI tools in patent drafting

The practical cost–benefit considerations of using AI tools in patent drafting. Explore how AI can improve efficiency and consistency while addressing concerns around accuracy, oversight, implementation costs, and risk, helping IP professionals determine where these tools deliver real value in the drafting process.

Cross-Border Litigation: Forum Selection and Competing Jurisdictions

Evolving dynamics of cross-border patent litigation, with a focus on strategic forum selection and the growing competition between courts.

Litigation Updates from UPC, USA, Asia, and More

Minimise your patent portfolio exposure on the global level by gaining first-hand insights from on-the-ground updates from leading patent litigators.

Why is LSPN Europe chosen as the go-to event for in-house IP strategists? Because we care about the content, balance of conversation and assisting the industry with the latest insights.